双重αVβ8整合素与PD-1阻断克服TGFβ介导的B细胞抑制以增强抗肿瘤免疫
该研究利用空间转录组学和多路免疫荧光表征胶质母细胞瘤(GBM)中B细胞邻域,发现髓系细胞通过TGFβ通路与B细胞相互作用;药物或遗传性TGFβ阻断可扩增瘤内B细胞并与PD-1抑制协同增强生存,双治疗小鼠中60%肿瘤被清除,疗效依赖B细胞。
要点
- GBM中髓系细胞经TGFβ通路与B细胞相互作用,驱动B细胞进入调节性状态。
- TGFβ阻断联合PD-1抑制使双治疗小鼠60%肿瘤被清除,疗效依赖B细胞。
- 双αVβ8/PD-1阻断降低B细胞介导的CD8⁺T细胞细胞毒性抑制并增加浆母细胞分化。
核心结论
- 靶向TGFβ信号(抗αVβ8阻断剂)可通过多种可能机制影响抗肿瘤免疫,其中与PD-1检查点阻断协同挽救B细胞功能是重点。
- 瘤内B细胞免疫在增强脑肿瘤免疫治疗中起关键作用。
研究设计与样本
- 研究采用空间分辨转录组学和多路免疫荧光表征GBM中B细胞邻域。
- 研究构建条件性敲除小鼠以在体内研究TGFβ信号对B细胞功能和存活的影响。
- 研究将TGFβ阻断与PD-1抑制联合以评估联合抗胶质瘤疗效。
主要发现
- 髓系细胞是GBM中通过TGFβ通路与B细胞相互作用的主要细胞。
- 药物或遗传性TGFβ阻断扩增瘤内B细胞,并与PD-1抑制协同增强生存,双治疗小鼠中60%肿瘤被清除。
- 疗效关键依赖B细胞,B细胞耗竭消除生存获益。
- 双αVβ8/PD-1阻断降低B细胞介导的CD8⁺T细胞细胞毒性抑制并增加浆母细胞分化。
- 在RagKO小鼠中的部分疗效提示先天免疫的辅助作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy has revolutionized cancer treatment but has yet to be translated into brain tumors. Studies in other solid tumors suggest a central role of B-cell immunity in driving immune checkpoint blockade efficacy. In glioblastoma (GBM), tumor B cells are driven into a regulatory B-cell state that suppresses immune activation and T-cell function. METHODS: We used spatially resolved transcriptomics and multiplex immunofluorescence to characterize B-cell neighborhoods within GBM and identify enhanced TGFβ-signaling between myeloid and B cells. We generated conditional knockouts to investigate the effects of TGFβ signaling on B-cell function and survival in vivo. Additionally, we combined TGFβ blockade with PD-1 inhibition to evaluate their combined anti-glioma efficacy. RESULTS: Our findings reveal that myeloid cells are the primary interactors with B cells in GBM through the TGFβ pathway. Pharmacological or genetic TGFβ blockade expanded intratumoral B cells and synergized with PD-1 inhibition to enhance survival (60% tumor eradication in dual-treated mice). Therapeutic efficacy critically depended on B cells, as their depletion abolished survival benefits. Dual αVβ8/PD-1 blockade reduced B-cell-mediated suppression of CD8⁺ T-cell cytotoxicity and increased plasmablast differentiation, while partial efficacy in RagKO mice implicated ancillary roles for innate immunity. CONCLUSION: Targeting TGFβ signaling using an anti-αVβ8 blocker can impact anti-tumor immunity through different possible mechanisms, of which we highlight the rescuing of B-cell function through synergy with PD-1 checkpoint blockade therapy. Our work underscores the critical role of intratumoral B-cell immunity in enhancing immunotherapy against brain tumors.
引用
- Hou D, Wang S, Castro BA, et al. Dual aVß8 Integrin and PD-1 Blockade Overcomes TGFβ-Mediated B-Cell Suppression to Enhance Anti-Tumor Immunity. Neuro Oncol. 2025. PMID: 40269603. doi:10.1093/neuonc/noaf106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。